Compare · ARGX vs SOPH
ARGX vs SOPH
Side-by-side comparison of argenx SE (ARGX) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.96B, about 141.1x SOPH ($375.5M).
- Over the past year, ARGX is up 50.5% and SOPH is up 64.1% - SOPH leads by 13.6 points.
- SOPH has been more active in the news (23 items in the past 4 weeks vs 4 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- argenx SE
- SOPHiA GENETICS SA
- Price
- $853.73-5.62%
- $5.25-2.42%
- Market cap
- $52.96B
- $375.5M
- 1M return
- +4.55%
- +4.17%
- 1Y return
- +50.48%
- +64.06%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 4
- 23
- Recent ratings
- 25
- 13
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest SOPH
- Chief Financial Officer Cardoza George sold $4,164 worth of Ordinary Shares (774 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.25% to 310,684 units (SEC Form 4) to satisfy withholding obligation
- President Muken Ross sold $2,270 worth of Ordinary Shares (422 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.06% to 680,489 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by SOPHiA GENETICS SA
- Director Cox Troy was granted 19,724 units of Ordinary Shares, increasing direct ownership by 6% to 328,743 units (SEC Form 4)
- Director Ossipow Vincent was granted 19,724 units of Ordinary Shares, increasing direct ownership by 4% to 522,860 units (SEC Form 4)
- Director Hibbs Kathy L was granted 19,724 units of Ordinary Shares, increasing direct ownership by 22% to 109,492 units (SEC Form 4)
- Director Hirsch Didier was granted 19,724 units of Ordinary Shares, increasing direct ownership by 9% to 240,220 units (SEC Form 4)
- Director Cossery Jean-Michel was granted 19,724 units of Ordinary Shares, increasing direct ownership by 11% to 206,212 units (SEC Form 4)
- SEC Form 6-K filed by SOPHiA GENETICS SA
- SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting